Research Programs-Signal Transduction

信号转导计划（STRP）是从先前的乳腺癌研究发展而来的 方案（BCRP）。这一变化是在认识到信号分子现在是 新的癌症治疗的主要目标，这些目标超越了个体疾病的界限 比如乳腺癌STRP教师分享在理解信号转导过程的兴趣， 开发新型癌症疗法的目的。为此，STRP利用了 耶鲁大学的基础信号转导研究，以及信号转导的日益增长的翻译重要性， 作为癌症治疗靶点的转导分子。在上一个项目期间， 非受体酪氨酸激酶成为FDA批准药物的有效靶点。进行的研究 STRP将在受体及其调节的途径中识别新的治疗靶点，并促进 通过个性化医疗来最好地使用这些药物。STRP的总体目标是促进基本的 研究导致信号转导研究的主要领域的快速治疗发展，1）信号 转导; 2）细胞内信号通路; 3）细胞极化和细胞骨架;以及4） 亚细胞蛋白运输。这些目标将通过每月的科技和技术审查小组会议实现; 试点/发展奖，促进新的方法，新的合作，和翻译工作;通过 年度务虚会;通过与发展治疗计划的整合， 翻译发展;并通过与YCC的其他计划交叉施肥。联合领导人，博士。 约瑟夫·施莱辛格在阐明生长因子受体信号方面做出了无与伦比的贡献 以及开发抑制信号转导的基于结构的抗癌药物 分子。大卫博士F.斯特恩继续担任前体BCRP的共同领导人， 开发Stern博士在理解HER 2/ErbB 2方面取得了重要进展， 抗HER 2药物的快速发展，他一直对合理的分子诊断感兴趣 基于信号传导的原理。该计划的26名成员的杰出教师包括 两名成员的国家科学院和医学研究所，几名成员的 美国艺术与科学学院和欧洲分子生物学组织，美国国立卫生研究院优秀奖获得者，和协会。 YCC基础科学主任。程序专业知识包括信号的基本方面 转导、整联蛋白和皮质细胞骨架以及蛋白质运输和分选。一个重要的目标将是 通过增加信号转导生物学家与细胞之间的交流， 结构/贩运问题专家。在上一个资助期内，BCRP或STRP的成员发表了365篇与癌症相关的文章， 2009年，共有200多篇论文，其中4.4%是方案内合作，20.8%是方案间合作。 （一些联合出版物没有列出，因为它们早于YCC成员）。的 科学技术研究计划目前有来自九个部门的二十五名成员，研究经费总额为一千一百三十万美元 直接费用（共计1，640万美元），170万美元直接费用（共计280万美元）由国家癌症研究所供资，800万美元直接费用（共计280万美元）由国家癌症研究所供资。 直接费用（共计1 180万美元）是同行审查的其他费用。

The Signal Transduction Program (STRP) has evolved from the antecedent Breast Cancer Research Program (BCRP). This change was accomplished with recognition that signaling molecules are now the leading targets for novel cancer therapies and that these targets transcend boundaries of individual diseases like breast cancer. STRP faculty share an interest in understanding signal transduction processes for the purpose of developing novel cancer therapies. Towards this end, the STRP capitalizes on the quality of fundamental signal transduction research at Yale, and the growing translational importance of signal transduction molecules as cancer therapeutic targets. During the last project period, several receptor and non-receptor tyrosine kinases emerged as validated targets for FDA-approved drugs. Research by the STRP will identify new therapeutic targets among receptors and the pathways they regulate, and facilitate best use of these drugs through personalized medicine. The overall goal of the STRP is to foster basic research leading to rapid therapeutic development in major areas of Signal Transduction research, 1) Signal Transduction; 2) Intracellular Signaling Pathways; 3) Cell Polarization and the Cytoskeleton; and 4) Subcellular Protein Trafficking. These goals will be achieved through the monthly STRP meetings; through Pilot/Developmental awards that foster new approaches, hew collaborations, and translational work; through the annual retreat; through integration with the Developmental Therapeutics Program for streamlined translational development; and by cross-fertilization with other Programs of the YCC. The co-Leader, Dr. Joseph Schlessinger, has made unparalleled contributions in elucidation of growth factor receptor signal transduction, and in development of structure-based anti-cancer drugs that inhibit signal transduction molecules. Dr. David F. Stern continues as co-leader from the precursor BCRP from which the STRP developed. Dr. Stern has made important advances in understanding HER2/ErbB2 that have facilitated the rapid development of anti-HER2 drugs, and he has long been interested in rational molecular diagnostics based on principles of signal transduction. The distinguished faculty of this program of 26 members includes two members of both the National Academy of Sciences and the Institute of Medicine, several members of the American Academy of Arts & Sciences and EMBO, NIH MERIT award recipients, and the Assoc. Director for Basic Science of the YCC. Program expertise encompasses fundamental aspects of signal transduction, integrins and cortical cytoskeleton, and protein trafficking and sorting. An important goal will be the generation of novel ideas through increased communication of signal transduction biologists with cell structure/trafficking experts. In the last grant period, members of the BCRP or STRP published 365 cancerrelated papers, of which 4.4% represented intraprogrammatic collaborations, and 20.8% were interprogrammatic. (A number of joint publications are not listed since they predate YCC membership). The STRP presently has twenty-five members from nine departments, with total research funding of $11.3 million direct costs ($16.4 million total), $1.7 million direct costs ($2.8 million total) is NCI-funded and $8.0 million direct costs ($11.8 million total) is other peer-reviewed.